PolyPid (PYPD) Stock Price
PolyPid Price
The consensus 12-month price target for PolyPid is 13.26 USD, about 157.7% above where the stock trades today. Of 10 analysts, 9 rate the stock a buy — an overall Buy consensus. The stock trades about 63% above its 52-week low.
PolyPid stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of PolyPid over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how PolyPid stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing PolyPid's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | PolyPid Price |
|---|---|
| 8/24/2026 | 5.14 USD |
| 8/21/2026 | 5.10 USD |
| 8/20/2026 | 5.08 USD |
| 8/19/2026 | 4.79 USD |
| 8/18/2026 | 4.64 USD |
| 8/17/2026 | 4.77 USD |
| 8/14/2026 | 4.74 USD |
| 8/13/2026 | 4.78 USD |
| 8/12/2026 | 4.69 USD |
| 8/10/2026 | 4.77 USD |
| 8/7/2026 | 4.84 USD |
| 8/6/2026 | 4.81 USD |
| 8/5/2026 | 4.53 USD |
| 8/4/2026 | 4.49 USD |
| 8/3/2026 | 4.36 USD |
| 7/31/2026 | 4.29 USD |
| 7/30/2026 | 4.37 USD |
| 7/29/2026 | 4.03 USD |
| 7/27/2026 | 4.06 USD |
| 7/23/2026 | 4.24 USD |
| 7/22/2026 | 4.00 USD |
| 7/21/2026 | 3.74 USD |
| 7/20/2026 | 5.15 USD |
| 7/17/2026 | 5.37 USD |
| 7/16/2026 | 5.19 USD |
| 7/15/2026 | 5.21 USD |
| 7/14/2026 | 5.35 USD |
| 7/13/2026 | 5.16 USD |
| 7/10/2026 | 5.23 USD |
| 7/9/2026 | 5.42 USD |
| 7/8/2026 | 5.22 USD |
| 7/7/2026 | 5.33 USD |
| 7/6/2026 | 5.11 USD |
| 7/2/2026 | 5.02 USD |
| 7/1/2026 | 5.05 USD |
| 6/30/2026 | 5.08 USD |
| 6/29/2026 | 4.97 USD |
| 6/26/2026 | 4.75 USD |
| 6/25/2026 | 4.57 USD |
| 6/24/2026 | 4.76 USD |
| 6/23/2026 | 4.99 USD |
| 6/22/2026 | 4.79 USD |
| 6/18/2026 | 4.74 USD |
| 6/17/2026 | 4.56 USD |
| 6/16/2026 | 4.66 USD |
| 6/15/2026 | 4.66 USD |
| 6/12/2026 | 4.62 USD |
| 6/11/2026 | 4.57 USD |
| 6/10/2026 | 4.51 USD |
| 6/9/2026 | 4.57 USD |
| 6/8/2026 | 4.62 USD |
| 6/5/2026 | 4.50 USD |
| 6/4/2026 | 4.83 USD |
| 6/3/2026 | 4.72 USD |
| 6/2/2026 | 4.87 USD |
| 6/1/2026 | 5.07 USD |
| 5/29/2026 | 4.72 USD |
| 5/28/2026 | 4.76 USD |
| 5/27/2026 | 4.77 USD |
| 5/26/2026 | 4.84 USD |
| 5/22/2026 | 5.02 USD |
| 5/21/2026 | 4.83 USD |
| 5/20/2026 | 4.85 USD |
| 5/19/2026 | 4.76 USD |
| 5/18/2026 | 4.73 USD |
| 5/15/2026 | 4.46 USD |
| 5/14/2026 | 4.38 USD |
| 5/13/2026 | 4.22 USD |
| 5/4/2026 | 4.48 USD |
| 4/22/2026 | 4.71 USD |
| 4/21/2026 | 4.54 USD |
| 4/20/2026 | 4.69 USD |
| 4/17/2026 | 4.74 USD |
| 4/16/2026 | 4.66 USD |
| 4/15/2026 | 4.72 USD |
| 4/14/2026 | 4.42 USD |
| 4/13/2026 | 4.40 USD |
| 4/10/2026 | 4.31 USD |
| 4/9/2026 | 4.37 USD |
| 4/8/2026 | 4.23 USD |
| 4/7/2026 | 4.12 USD |
| 4/6/2026 | 4.24 USD |
| 4/2/2026 | 4.39 USD |
| 4/1/2026 | 4.39 USD |
| 3/31/2026 | 4.38 USD |
| 3/30/2026 | 4.21 USD |
| 3/27/2026 | 4.28 USD |
| 3/26/2026 | 4.32 USD |
| 3/25/2026 | 4.29 USD |
| 3/24/2026 | 4.21 USD |
| 3/23/2026 | 4.15 USD |
| 3/20/2026 | 4.16 USD |
| 3/19/2026 | 4.37 USD |
| 3/18/2026 | 4.39 USD |
| 3/17/2026 | 4.39 USD |
| 3/16/2026 | 4.56 USD |
| 3/15/2026 | 4.40 USD |
| 3/13/2026 | 4.19 USD |
| 3/12/2026 | 4.19 USD |
| 3/11/2026 | 4.17 USD |
| 3/10/2026 | 4.35 USD |
| 3/9/2026 | 4.32 USD |
| 3/8/2026 | 4.18 USD |
| 3/6/2026 | 4.19 USD |
| 3/5/2026 | 4.19 USD |
| 3/4/2026 | 4.23 USD |
| 3/3/2026 | 4.25 USD |
| 3/2/2026 | 4.23 USD |
| 3/1/2026 | 4.34 USD |
| 2/27/2026 | 4.25 USD |
| 2/26/2026 | 4.25 USD |
| 2/25/2026 | 4.22 USD |
| 2/24/2026 | 4.29 USD |
| 2/23/2026 | 4.25 USD |
| 2/22/2026 | 4.24 USD |
| 2/20/2026 | 4.18 USD |
| 2/19/2026 | 4.18 USD |
| 2/18/2026 | 4.27 USD |
| 2/17/2026 | 4.25 USD |
| 2/16/2026 | 4.41 USD |
| 2/13/2026 | 4.43 USD |
| 2/12/2026 | 4.43 USD |
| 2/11/2026 | 4.59 USD |
| 2/10/2026 | 4.62 USD |
| 2/9/2026 | 4.68 USD |
| 2/8/2026 | 4.58 USD |
| 2/6/2026 | 4.52 USD |
| 2/5/2026 | 4.52 USD |
| 2/4/2026 | 4.35 USD |
| 2/3/2026 | 4.41 USD |
| 2/2/2026 | 4.74 USD |
| 2/1/2026 | 4.87 USD |
| 1/30/2026 | 4.58 USD |
| 1/29/2026 | 4.58 USD |
| 1/28/2026 | 4.71 USD |
| 1/27/2026 | 4.72 USD |
| 1/26/2026 | 4.80 USD |
| 1/25/2026 | 4.55 USD |
| 1/23/2026 | 4.78 USD |
| 1/22/2026 | 4.78 USD |
| 1/21/2026 | 4.81 USD |
| 1/20/2026 | 4.59 USD |
| 1/19/2026 | 4.46 USD |
| 1/16/2026 | 4.37 USD |
| 1/15/2026 | 4.37 USD |
| 1/14/2026 | 4.39 USD |
| 1/13/2026 | 4.34 USD |
| 1/12/2026 | 4.41 USD |
| 1/11/2026 | 4.65 USD |
| 1/9/2026 | 4.64 USD |
| 1/8/2026 | 4.64 USD |
| 1/7/2026 | 4.65 USD |
| 1/6/2026 | 4.77 USD |
| 1/5/2026 | 4.57 USD |
| 1/4/2026 | 4.47 USD |
| 1/2/2026 | 4.35 USD |
| 1/1/2026 | 4.35 USD |
| 12/31/2025 | 4.34 USD |
| 12/30/2025 | 4.34 USD |
| 12/29/2025 | 4.38 USD |
| 12/28/2025 | 4.39 USD |
| 12/26/2025 | 4.07 USD |
| 12/25/2025 | 4.07 USD |
| 12/24/2025 | 4.02 USD |
| 12/23/2025 | 4.02 USD |
| 12/22/2025 | 3.90 USD |
| 12/21/2025 | 3.98 USD |
| 12/19/2025 | 3.97 USD |
| 12/18/2025 | 3.97 USD |
| 12/17/2025 | 3.92 USD |
| 12/16/2025 | 3.93 USD |
| 12/15/2025 | 3.95 USD |
| 12/14/2025 | 4.00 USD |
| 12/12/2025 | 3.92 USD |
| 12/11/2025 | 3.92 USD |
| 12/10/2025 | 3.98 USD |
| 12/9/2025 | 4.01 USD |
| 12/8/2025 | 3.98 USD |
| 12/7/2025 | 3.98 USD |
| 12/5/2025 | 3.97 USD |
| 12/4/2025 | 3.97 USD |
| 12/3/2025 | 3.94 USD |
| 12/2/2025 | 3.96 USD |
| 12/1/2025 | 3.78 USD |
| 11/30/2025 | 3.88 USD |
| 11/28/2025 | 3.95 USD |
| 11/27/2025 | 3.95 USD |
| 11/26/2025 | 3.80 USD |
| 11/25/2025 | 3.80 USD |
| 11/24/2025 | 3.68 USD |
| 11/23/2025 | 3.62 USD |
| 11/21/2025 | 3.60 USD |
| 11/20/2025 | 3.60 USD |
| 11/19/2025 | 3.63 USD |
| 11/18/2025 | 3.60 USD |
| 11/17/2025 | 3.64 USD |
| 11/16/2025 | 3.64 USD |
| 11/14/2025 | 3.59 USD |
| 11/13/2025 | 3.59 USD |
| 11/12/2025 | 3.58 USD |
| 11/11/2025 | 3.75 USD |
| 11/10/2025 | 3.76 USD |
| 11/9/2025 | 3.74 USD |
| 11/7/2025 | 3.65 USD |
| 11/6/2025 | 3.65 USD |
| 11/5/2025 | 3.80 USD |
| 11/4/2025 | 3.79 USD |
| 11/3/2025 | 3.84 USD |
| 11/2/2025 | 3.79 USD |
| 10/31/2025 | 3.83 USD |
| 10/30/2025 | 3.83 USD |
| 10/29/2025 | 3.84 USD |
| 10/28/2025 | 3.80 USD |
| 10/27/2025 | 3.71 USD |
| 10/26/2025 | 3.61 USD |
| 10/23/2025 | 3.44 USD |
| 10/22/2025 | 3.44 USD |
| 10/21/2025 | 3.18 USD |
| 10/20/2025 | 3.22 USD |
| 10/19/2025 | 3.20 USD |
| 10/16/2025 | 3.27 USD |
| 10/15/2025 | 3.35 USD |
| 10/14/2025 | 3.35 USD |
| 10/13/2025 | 3.34 USD |
| 10/12/2025 | 3.34 USD |
| 10/9/2025 | 3.15 USD |
| 10/8/2025 | 3.33 USD |
| 10/7/2025 | 3.43 USD |
| 10/6/2025 | 3.33 USD |
| 10/5/2025 | 3.54 USD |
| 10/2/2025 | 3.50 USD |
| 10/1/2025 | 3.46 USD |
| 9/30/2025 | 3.37 USD |
| 9/29/2025 | 3.34 USD |
| 9/28/2025 | 3.33 USD |
| 9/25/2025 | 3.34 USD |
| 9/24/2025 | 3.37 USD |
| 9/23/2025 | 3.45 USD |
| 9/22/2025 | 3.44 USD |
| 9/21/2025 | 3.55 USD |
| 9/18/2025 | 3.45 USD |
| 9/17/2025 | 3.50 USD |
| 9/16/2025 | 3.37 USD |
| 9/15/2025 | 3.43 USD |
| 9/14/2025 | 3.39 USD |
| 9/11/2025 | 3.47 USD |
| 9/10/2025 | 3.45 USD |
| 9/9/2025 | 3.45 USD |
| 9/8/2025 | 3.49 USD |
| 9/7/2025 | 3.46 USD |
| 9/4/2025 | 3.45 USD |
| 9/3/2025 | 3.40 USD |
| 9/2/2025 | 3.42 USD |
| 9/1/2025 | 3.41 USD |
| 8/28/2025 | 3.35 USD |
| 8/27/2025 | 3.38 USD |
| 8/26/2025 | 3.42 USD |
PolyPid Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
PolyPid Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEk USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | 15.00 | 8.00 | 45.00 | 95.00 | 152.00 |
| – | – | – | – | – | – | – | – | – | – | – | – | -46.67 | 462.50 | 111.11 | 60.00 |
| – | – | – | – | – | – | – | – | – | – | – | -6.67 | -12.50 | -2.22 | -1.05 | -0.66 |
| -1,000.00 | -1,000.00 | -1,000.00 | -1,000.00 | -1,000.00 | -1,000.00 | -1,000.00 | -1,000.00 | -1,000.00 | -1,000.00 | -1,000.00 | -1,000.00 | -1,000.00 | -1,000.00 | -1,000.00 | -1,000.00 |
| -11.00 | -10.00 | -13.00 | -18.00 | -18.00 | -26.00 | -42.00 | -38.00 | -22.00 | -28.00 | -32.00 | -33.00 | -27.00 | 5.00 | 75.00 | 160.00 |
| – | – | – | – | – | – | – | – | – | – | – | -220.00 | -337.50 | 11.11 | 78.95 | 105.26 |
| -8.00 | -11.00 | -54.00 | 5.00 | -6.00 | -35.00 | -40.00 | -39.00 | -23.00 | -29.00 | -34.00 | -14.00 | -18.00 | -3.00 | 24.00 | 58.00 |
| 166.67 | 37.50 | 390.91 | -109.26 | -220.00 | 483.33 | 14.29 | -2.50 | -41.03 | 26.09 | 17.24 | -58.82 | 28.57 | -83.33 | -900.00 | 141.67 |
| 20.59 | 20.59 | 0.57 | 20.59 | 0.89 | 1.23 | 1.25 | 1.31 | 1.65 | 7.54 | 20.59 | 20.59 | 20.59 | 20.59 | 20.59 | 20.59 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales PolyPid generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue PolyPid retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare PolyPid's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares PolyPid has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against PolyPid's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
PolyPid stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
PolyPid Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
PolyPid business model & stock analysis
PolyPid SWOT Analysis
Strengths
PolyPid Ltd has several strengths that contribute to its competitive advantage:
PolyPid has developed a novel drug delivery system that enables the controlled release of antibiotics directly at the site of infection, improving efficacy and reducing potential side effects.
The company has a robust portfolio of patents protecting its technology and product candidates, providing a barrier to entry for potential competitors.
PolyPid is led by a skilled management team with extensive expertise in the pharmaceutical and medical device industry, ensuring effective strategic decision-making and execution.
Weaknesses
Despite its strengths, PolyPid Ltd also faces some weaknesses that need to be addressed:
At the moment, PolyPid has a relatively small pipeline of product candidates, which may limit its revenue potential and growth opportunities.
Developing and gaining regulatory approval for new medical devices can be a complex and time-consuming process, posing potential challenges to PolyPid's product development timeline and market entry.
PolyPid relies on strategic collaborations and partnerships with larger pharmaceutical companies to advance its products, making it vulnerable to the decisions and priorities of its partners.
Opportunities
PolyPid Ltd can take advantage of several opportunities in the market:
The increasing prevalence of antibiotic-resistant infections creates a significant market opportunity for PolyPid's targeted drug delivery system, providing solutions for improved patient outcomes.
PolyPid can explore expanding its drug delivery technology beyond antibiotics and into other therapeutic areas, such as antifungals or chemotherapy drugs, diversifying its product portfolio.
Forming strategic partnerships and licensing agreements with international pharmaceutical companies can facilitate global market expansion and enhance PolyPid's reach.
Threats
PolyPid Ltd must also be aware of potential threats in the market:
The pharmaceutical and medical device industry is highly competitive, with established companies and emerging startups developing innovative drug delivery technologies, posing a threat to PolyPid's market share.
Stringent regulatory requirements and potential delays in reimbursement decisions can impede market adoption and limit the widespread use of PolyPid's products.
Economic downturns, changes in healthcare policies, and pricing pressures can impact the healthcare industry, potentially affecting PolyPid's market potential and revenue growth.
PolyPid Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
PolyPid Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
PolyPid historical P/E ratio, EBIT multiple, and P/S ratio
PolyPid annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
PolyPid shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
PolyPid stock splits
Current PolyPid forecasts and price targets in August 2026
Analyst Price Targets 2026PolyPid Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 7/21/2026 | Maintained | Buy | – | |
| 2/11/2026 | Maintained | Buy | – | |
| 11/13/2025 | Maintained | Buy | 49 | |
| 8/14/2025 | Maintained | Buy | – | |
| 8/13/2025 | Maintained | Buy | – | |
| 6/18/2025 | Maintained | Buy | 49 | |
| 6/17/2025 | Maintained | Market Outperform | – | |
| 6/9/2025 | Maintained | Buy | – | |
| 4/14/2025 | Maintained | Buy | – | |
| 12/26/2024 | Maintained | Buy | – |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
PolyPid Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 8/12/2026 | -0.39USD | - | 0.00USD | - | 2026 Q2 |
| 5/13/2026 | -0.44USD | - | 0.00USD | - | 2026 Q1 |
| 2/11/2026 | -0.34USD | - | 0.00USD | - | 2025 Q4 |
| 8/13/2025 | -0.56USD | - | 0.00USD | - | 2025 Q2 |
| 11/13/2024 | -1.02USD | - | 0.00USD | - | 2024 Q3 |
| 5/8/2024 | -3.85USD | - | -USD | - | 2024 Q1 |
| 2/6/2024 | -3.49USD | - | 0.00USD | - | 2023 Q4 |
| 11/7/2023 | -0.23USD | - | 0.00USD | - | 2023 Q3 |
| 8/8/2023 | -0.48USD | - | 0.00USD | - | 2023 Q2 |
| 5/9/2023 | -0.57USD | - | 0.00USD | - | 2023 Q1 |
PolyPid shareholder structure
| % | Name |
|---|---|
18.53687% | |
5.86568% | |
4.63975% | |
4.39910% | |
1.25015% | |
1.19850% |
PolyPid Beneficial Ownership Filings (SEC 13D/G)
PolyPid Executives and Management Board
12 members · avg. age 61 · 25 % women
Dr. Noam Emanuel (62)
Chief Scientific Officer · since 2008
1.09 M USD
Management
Ms. Dikla Akselbrad (50)
Chief Executive Officer, Director · since 2014
Mr. Ori Warshavsky (44)
Chief Operating Officer - US
Ms. Dalit Hazan (51)
Senior Vice President - Research and Development and Regulatory Affairs
Dr. Shaul Mukhtar (66)
Chief Operating Officer, Executive Vice President
Board of Directors
Mr. Jacob Harel (66)
Independent Chairman of the Board
Dr. Yechezkel Barenholz (79)
Independent Director
Mr. Nir Dror (45)
Independent Director
Mr. Chaim Hurvitz (65)
Independent Director
Dr. Itzhak Krinsky (69)
Independent Director
Mrs. Anat Segal (55)
Independent Director
PolyPid Supply Chain
Frequently asked questions about PolyPid
PolyPid Ltd is a pharmaceutical company specializing in the development and commercialization of novel sustained-release drug delivery solutions. Their unique proprietary technology, called D-Plex™, allows for the controlled release of drugs over an extended period, enhancing therapeutic efficacy and reducing side effects. PolyPid focuses on advanced drug delivery solutions for the prevention and treatment of surgical site infections (SSIs) and various other medical conditions. By leveraging their expertise in polymer science and drug delivery, PolyPid aims to improve patient outcomes and reduce healthcare costs.
PolyPid Ltd is primarily active in the pharmaceutical industry.
Some of the main competitors of PolyPid Ltd in the market include Johnson & Johnson, Merck & Co., Inc., Abbott Laboratories, and Pfizer Inc.
PolyPid Ltd is an innovative pharmaceutical company that focuses on developing and commercializing novel antibiotics and drug delivery solutions. Founded in [year], PolyPid is headquartered in Israel and has rapidly gained recognition for its groundbreaking technologies. With a strong emphasis on addressing unmet medical needs, PolyPid has been dedicated to creating advanced therapeutic solutions for the prevention and treatment of surgical site infections. The company's proprietary PLEX technology enables the localized and sustained release of drugs, leading to improved patient outcomes. PolyPid Ltd continues to be a leader in the field, revolutionizing drug delivery systems and making significant advancements in the pharmaceutical industry.
Some of the significant milestones achieved by PolyPid Ltd include the successful completion of their Phase III pivotal clinical trial for D-PLEX 100, a drug-device combination product for the prevention of surgical site infections. The company also received FDA Breakthrough Therapy Designation for D-PLEX 100, which demonstrates its potential to address an unmet medical need. In addition, PolyPid Ltd entered into collaboration agreements with leading medical institutions and received grants and awards for its innovative drug delivery technologies. These achievements highlight PolyPid Ltd's progress in developing effective solutions for preventing infections in surgical procedures.
PolyPid Ltd is primarily present in Israel.
PolyPid Ltd represents innovative solutions in the field of localized drug delivery, focusing on preventing surgical site infections (SSIs). With a commitment to patient well-being and surgical outcome improvement, PolyPid's corporate philosophy revolves around three core values: excellence, integrity, and collaboration. The company strives for excellence by developing cutting-edge drug delivery platforms that target the specific needs of healthcare providers and patients. It upholds integrity by conducting business with transparency, adhering to ethical standards, and maintaining trust with stakeholders. PolyPid also emphasizes collaboration through partnerships with key opinion leaders and healthcare professionals to drive continued innovation in infection prevention.
Analysts currently set an average price target of 12.50 USD for the PolyPid stock (median: 13.26 USD), implying +142.9 % versus the latest price. The consensus is based on 10 analyst ratings.
10 analysts currently rate the PolyPid stock: 9 recommend buying, 1 holding and 0 selling. For 2026, analysts expect PolyPid to generate revenue of 15.00 M USD and earnings per share of -0.68 USD.
Converted at the current exchange rate, the PolyPid share trades at 4.41 EUR (5.14 USD).
The PolyPid share (PYPD) is listed on 1 stock exchanges, including: NASDAQ (PYPD).
PolyPid Ltd is an emerging company specializing in the development of innovative drug delivery platforms. The company was founded in Israel in 2008 and has since developed and brought to market a diverse portfolio of products, allowing it to attract more and more customers and partners. PolyPid Ltd's business model is divided into different divisions, all aimed at the development of drugs and improving medical treatment options. One of the company's main products is the Bacterial and Cellular Affinity Technology (BACT) System, which allows for controlled drug release. With this system, drugs can be administered over a specific period of time, resulting in targeted and effective treatment. Another successful offering from the company is the PLEX™ System, which is also based on drug release. Polyethylene oxide (PEO) implants are implanted into the body, slowly releasing medication. The PLEX™ System was specifically designed for use in orthopedic surgeries and has proven effective in patients with joint diseases. The D-PLEX™ System is also offered, particularly for the treatment of post-operative pain. In this case, the pain medication Dexamethasone is released over a longer period of time, reducing post-operative pain. PolyPid Ltd also focuses on developing products for cancer therapy. With the Cancer Targeted Technology (CTT) System, the company has developed a platform that allows for targeted release of anti-cancer drugs. This enables the specific targeting of tumor cells while protecting healthy tissue. The product portfolio is complemented by the Xtrap™ System, developed for wound treatment. A special agent is used to promote wound healing and accelerate the healing process. PolyPid Ltd is also strategically working to increase the market success of its products by entering into collaborations and partnerships with other companies. The company has announced collaborations with Allergan and a leading animal health company, among others. PolyPid Ltd's business model is based on the idea of developing unique and high-quality products for the medical industry and serving customers worldwide. The company continuously works to improve its technologies and develop new products tailored to the needs of patients. Through a combination of research and development, innovation, and strategic partnerships, PolyPid Ltd has established itself as a successful company in the medical industry.
The expected revenue of PolyPid is 15.00 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of PolyPid is -14.09 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of PolyPid is currently -7.52. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the PolyPid stock.
The price-to-sales ratio (P/S) of PolyPid is currently 7.06. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the PolyPid stock.
The Eulerpool Quality Score for PolyPid is 2/10.
The ISIN of PolyPid is IL0011326795. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of PolyPid is A2JNTB. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of PolyPid is PYPD. The ticker symbol is used to trade PolyPid shares on the stock exchange.
PolyPid paid dividends every year for the past 0 years.
PolyPid is assigned to the '—' sector.
The dividends of PolyPid are distributed in USD.
PolyPid stock
PolyPid Peer Group
PolyPid Ticker
PolyPid FIGI
All fundamentals and in-depth analysis of PolyPid
Our stock analysis for PolyPid stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of PolyPid. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.